İmmun Trombositopenik Purpura Tanı ve Tedavisine Güncel Yaklaşım

Year 2003, Volume: 1 Issue: 1, 73 - 78, 01.09.2003

Adalet Meral Güneş

Abstract

Idiopatik trombositopenik purpura ITP veya diğer adı ile primer immun trombositopenik purpura trombositlere karşı gelişen otoantikorların trombositleri retiküloendotelyal sistemde parçalaması ile karakterize hematolojik bir hastalıktır. Çocukluk ça- ğında %80 olguda spontan düzelmesine karşın bazı olgularda ciddi kanamalara yol açabilir

References

• 1. George JN, Woolf SH, Raskop GE, et al. Idiopathic Thrombocytopenic Purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
• 2. Lanzkowsky P. Disorders of platelets. In: Lanzkowsky P (ed). Manual of Pediatric Hematology and Oncology 2nd edition. New York, NY: Churchill Livingstone; 1995. p:185- 238.
• 3. Pearson HA. The spleen and disturbances of splenic function. In: Nathan DG, Oski FA (eds). Hematology of Infancy and Childhood. Philadelphia PA: Saunders; 1993. p.1058- 70.
• 4. Lammi AT, Lovric VA. Idiopathic thrombocytopenic purpura: An epidemiologic study. Pediatrics 1973; 83: 31-6.
• 5. Imbach P. Immune thrombocytopenic purpura. In: Lilleyman J, Hann I, Blanchette V (eds). Pediatric Hematology 2nd edition . London: Churchill Livingstone; 2000. p.437 – 53.
• 6. George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds). Williams Hematology. New York, NY: McGraw-Hill; 1995. p.1315 – 20.
• 7. Kurata Y, Miyagawa S, Kosugi S.High titer antinuclear antibodies, anti-SSA/Ro antiboies and antinuclear RNP antbodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71: 184 – 7.
• 8. Stasi S, Stipa E, Masi M. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203.
• 9. Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966; 68: 971-9.
• 10. den Ottolander GJ, Gratama JW, deKoning J, Brand A. Long term follow-up study of 168 patients with immune thrombocytopenia. Scand J haematol 1984; 32: 101-10.
• 11. Komrower GM, Watson GH. Prognosis in idiopathic thrombocytopenic purpura of chidhood. Arch Dis Child 1954; 29: 502-5.
• 12. Choi SI, McClure PD. Idiopathic thrombocytopenic purpura in childhood. Can Med Assoc J 1967; 97: 562-7.
• 13. Walker RW, Walker W. ‹diopathic thrombocytopenia, initial illness and long term follow up. Arch Dis Child 1984; 59: 316-22.
• 14. Ramos ME, Newman AJ, Gross S. Chronic thrombocytopenia in childhood. Pediatrics 1978; 92: 584-6.
• 15. Zaki M, Hassanein AA, Khalil AF. Childhood idiopathic thrombocytopenic purpura. Report of 60 cases from Kuwait. Journal of Tropical Pediatrics 1990; 36: 10-3.
• 16. Robb LG, Tiedeman K. Idiopathic thrombocytopenic purpura: predictors of chronic disease. Arch Dis Child 1990; 65: 502-6.
• 17. Imbach P, d’Apuzzo V, Hirt A. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
• 18. Woerner SJ, Abildgaard CF, french BN. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics 1981; 67: 453-60.
• 19. Schattner E, Bussel J. Mortality in immune thrombocytopenic purpura: report of seven case and consideration of prognostic indicators. Am J Hematol 1994; 46:120-6.
• 20. Blanchette VS, Luke B, Andrew M, et al. A prospective,randomized trial of high dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-95.
• 21. Belluci S, Charpak Y, Chastang C, Tobelem G. Low doses vs conventional doses of cortic›ids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood 1988; 71: 1165-9.
• 22. Ozsoylu S, Irken G, Karabent A. High dose intravenous methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. Eur J Haematol 1989; 42: 431.
• 23. Saag S, Koehnke R, caldwell JR, et al. Low dose long term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse effects. Am J Med 1994; 96:115-23.
• 24. Ozsoylu S, Sayli TR, Ozturk G. Oral megadose methylprednisolone versus intravenous immunglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 1993; 10:317- 21.
• 25. van Hoff J, Ritchey AK. Pulse methylprednisolone therapy acute childhood idiopathic thrombocytopenic purpura. J Pediatr 1988; 113:563- 6.
• 26. Albayrak D, Islek I, Kalayc› AG, Gürses N. Acute immune thrombocytopenic purpura: A comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin. J pediatr 1994; 125: 1004- 7.
• 27. Blanchette V, Imbach P , Andrew M, et al. Randomized trials of intravenous immunglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703- 7.
• 28. Imbach P, Wagner HP, Berchtold W. Intravenous immunglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; 2: 464- 6.
• 29. Bussel JB, Goldman A, Imbach P, Schulman I, Hilgartner MW. Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin. J Pediatr 1985; 106: 886- 90.
• 30. Bussel JB, Goldman A, Imbach p, Schulman I, Hilgartner MW. Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. J Pediatr 1983; 103: 651- 4.
• 31. Duhem C, Dicato MA, Ries F. Side effects of intravenous immune globulins. Clin Exp Immunol 1994 (suppl 1); 97: 79-83.
• 32. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high dose intravenous immunglobulin therapy: Frequency and risk factors. Ann Intern Med 1994; 121: 259–62.
• 33. Andrew M, Blancette VS, Adams M, et al. A multicenter study of the treatment of childhood immune thrombocytopenic purpura. with anti-D. J Pediatr 1992; 120:522- 7.
• 34. Borgna-Pignatti C, Battisti L, Zecca M, Locatelli F. Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular anti-D immunglobulins. Br J Haematol 1994; 88: 618- 20.
• 35. Zcrella JT, Martin LW, Lampkin BC. Emergency splenectomy for idiopathic thrombocytopenic purpura in children. J Pediatr Surg 1978; 13: 243- 6.
• 36. Davis PW, Williams DA, Shamberger RC. Immune thrombocytopenia: Surgical therapy and predictors of response. J Pediatr Surg 1991; 26: 407- 12.
• 37. Yang R, Han ZC. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura:An update. Int J Hematol 2000; 71:18- 24.
• 38. Najean Y, Rain JD, Billotey A. The site of destruction of autologous 111 In-labeled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 1997; 97: 547–50.
• 39. Lortan JE. Clinical annotation. Management of asplenic patients. Br J Haematol 1993; 84: 566-9.
• 40. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122: 187-8.
• 41. Hilgartner MW, Lanzkowsky P, Smith CH. The use of azothioprine in refractory idiopathic thrombocytopenic purpura in children. Acta Pediatr Scand 1970; 59: 409-15.
• 42. Weinblatt ME, Kochen J, Ortega J. Danazol for children with immune thrombocytopenic purpura. Am J Dis Child 1988; 142: 1317-9.
• 43. Cohn RJ, Schwyzer R, Hesseling PB, Poole JE, Naidoo J, Van Herden C. Alpha interferon therapy for severe chronic idiopathic thrombocytopenic purpura in children. Am J Hematol 1993; 43: 246-50.
• 44. Verhoef GE, Boonen S, Boogaerts MA. Ascorbate for the treatment of refractory idiopathic thrombocytopenic purpura. Br J Haematol 1990; 74: 234-5.